While major guidelines for hemophilia management emphasize individualized and patient-centered care, they often fall short of explicitly addressing how to achieve a life experience as close as possible to that of an individual without the condition. This concept, termed 'normalization,' shifts the focus beyond simply preventing bleeds to actively enabling full participation in life, requiring a deeper understanding of patient aspirations and tailored treatment strategies.

Guideline Context

Major guidelines, such as those from the World Federation of Hemophilia (WFH) and the National Hemophilia Foundation (NHF), already emphasize individualized treatment plans and patient-centered care.1 However, the 'normalization' concept takes this a step further by explicitly focusing on achieving a life experience as close as possible to that of an individual without hemophilia. While existing guidelines provide recommendations for prophylaxis and on-demand treatment, they may not always fully address the nuances of lifestyle integration.1 For example, the WFH guidelines recommend prophylaxis to maintain trough levels above 1%, but achieving 'normalization' might require higher trough levels in some individuals to support high-impact activities. This is where shared decision-making and a thorough understanding of the patient's goals become paramount.

Practical Strategies for Normalization

So how do we translate this concept into actionable steps? Start by actively listening to your patients. What are their aspirations? What activities do they want to participate in? What limitations do they perceive? This information forms the foundation for a personalized treatment plan. This includes discussing target trough levels for factor replacement therapy, exploring extended half-life products, and considering emerging therapies like emicizumab or gene therapy where appropriate.3 Openly discuss the risks and benefits of each approach, acknowledging that the 'best' treatment is the one that aligns with the patient's individual needs and preferences. Counsel patients about practical strategies for managing bleeds in different settings, such as schools, workplaces, or during travel. Equip them with the knowledge and resources they need to confidently navigate these situations.

Addressing Activity Levels

Participation in sports and physical activity is a key component of 'normalization'.2 For children and adolescents, this might involve participating in team sports or recreational activities. For adults, it could mean engaging in fitness programs or pursuing hobbies like hiking or cycling. The goal is to find activities that the patient enjoys and can safely participate in. This requires a careful assessment of bleeding risk and appropriate adjustments to the treatment regimen. For example, a patient who wants to play soccer might require higher factor levels or more frequent infusions than someone who prefers swimming. Discuss the use of protective gear, appropriate warm-up and cool-down routines, and strategies for managing minor injuries. Connect patients with resources like physical therapists or athletic trainers who have experience working with individuals with bleeding disorders. Remember, the goal is not to discourage activity but to enable it safely and effectively.

Psychosocial Well-being

Living with hemophilia can have a significant impact on psychosocial well-being. Chronic pain, anxiety about bleeding, and social stigma can all contribute to emotional distress. 'Normalization' also means addressing these challenges proactively. Screen patients for depression and anxiety, and provide referrals to mental health professionals as needed. Encourage participation in support groups or online communities where patients can connect with others who share similar experiences. Address issues related to body image and self-esteem, particularly in adolescents. Promote open communication within families and encourage parents to foster independence and self-advocacy in their children with hemophilia. Recognizing that the cost of hemophilia treatment can cause significant stress. Connect patients with financial assistance programs and resources to help them manage the economic burden of their condition.

Critique of the Normalization Concept

While 'normalization' represents a valuable shift in perspective, it is not without its limitations. The very definition of 'normal' is subjective and can vary significantly from person to person. Imposing a universal standard of 'normality' could inadvertently create unrealistic expectations or pressure patients to conform to a particular lifestyle. Furthermore, achieving 'normalization' may not always be feasible or desirable, particularly for individuals with severe hemophilia or those who have experienced significant joint damage. It's vital to acknowledge the individual's unique circumstances and tailor treatment goals accordingly. Access to comprehensive care, including specialized hemophilia treatment centers, remains a significant barrier for many patients, particularly those in rural or underserved areas. Additionally, the high cost of factor replacement therapy and emerging therapies can create significant financial challenges, limiting access to optimal treatment and hindering the pursuit of 'normalization'.

Clinical Implications

The most striking consequence of embracing "normalization" is the imperative for a fundamental shift in clinical practice. It moves beyond simply preventing bleeds to actively enabling a full, unrestricted life. This demands more than adherence to minimum trough levels, such as the 1% recommended by WFH guidelines. It requires clinicians to partner with patients, understanding their life goals and tailoring factor replacement therapy, including extended half-life products or emerging therapies like emicizumab, to support those aspirations. The evidence base for specific trough levels to achieve diverse activity goals is still developing, making shared decision-making crucial.

For the pharmaceutical industry, this evolving paradigm presents both challenges and opportunities. The focus on individualized outcomes will drive demand for therapies that offer greater flexibility, longer half-lives, and varied administration routes. Companies like BioMarin and Pfizer, developing gene therapies, or Chugai and Roche with emicizumab, are already responding to this need for innovative solutions that push beyond traditional prophylaxis. However, the economic burden of these advanced therapies on healthcare systems needs careful consideration, and industry must collaborate on access strategies.

Patients, in turn, gain a powerful voice in their care. The "normalization" concept empowers them to articulate their desired quality of life, not just their medical needs. This will necessitate robust patient education and support systems, connecting individuals with resources beyond the clinic, such as physical therapists or mental health professionals. While the subjective nature of "normal" means this journey will be unique for everyone, it represents a significant step towards truly patient-centered hemophilia care.

Key Takeaways
  • The Pivot The 'normalization' concept in hemophilia care shifts focus from simply preventing bleeds to proactively enabling a life experience as close as possible to that of an individual without hemophilia, emphasizing lifestyle integration and patient aspirations.
  • The Data WFH guidelines recommend prophylaxis to maintain trough levels above 1%, but achieving 'normalization' may require higher trough levels in some individuals to support high-impact activities.
  • The Action Actively engage patients in shared decision-making to establish personalized treatment plans, including target trough levels and therapy choices, that align with their individual goals for activity, psychosocial well-being, and overall quality of life.
Save as PDF

ART-2025-3

·

09/26

Drafted with AI assistance, reviewed and approved by the editorial team. This publication is intended for healthcare professionals, researchers, and life science industry professionals. Content is provided for informational and educational purposes only and does not constitute medical advice.


Authored by
Dana Prescott
Clinical Trial Writer & Podcast Host

I specialise in clinical trial methodology and drug development, from Phase I to post-approval. My reports cover what got studied, what did not, and why. Based in Boston, reporting globally.

Reviewed & published byMara Voss
Cite This Article

Prescott D, Voss M. Moving beyond deficiencies: normalization strategies in hemophilia care. The Life Science Feed. Published September 28, 2026. Updated September 28, 2026. Accessed October 1, 2026. https://thelifesciencefeed.com/haematology/hemophilia-a/practice/moving-beyond-deficiencies-normalization-strategies-in-hemophilia-care.

Editorial & AI Standards

All content is researched from peer-reviewed, open-access sources: published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.

Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.

Licence & Rights

© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.

Medical Disclaimer

The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

References

1. Chowdary P, Carcao M, Kenet G, Pipe SW. Haemophilia. Lancet. 2025;405(10480):736-750. doi:10.1016/S0140-6736(24)02139-1

2. Petrini P. Treatment strategies in children with hemophilia. Paediatr Drugs. 2002;4(7):427-37. doi:10.2165/00128072-200204070-00002

3. Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy for hemophilia: looking beyond factor expression. Exp Biol Med (Maywood). 2022;247(24):2223-2232. doi:10.1177/15353702221147565

The Life Science Feed
thelifesciencefeed.com • william.lopes@thelifesciencefeed.com